A first-in-human clinical trial of RTY-694 for Primary Sclerosing Cholangitis (PSC)
Latest Information Update: 29 Oct 2024
At a glance
- Drugs RTY 694 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; First in man
- 29 Oct 2024 New trial record
- 22 Oct 2024 According to a Rectify Pharma media release, RTY-694 was selected as the lead PFM for its hepatobiliary program and is advancing to first-in-human clinical trials for primary sclerosing cholangitis (PSC).